Published in Br J Pharmacol on February 26, 2007
Gum Arabic as Immunomodulator In Rheumatoid Arthritis Patients | NCT02804581
Histone deacetylase inhibitor induces DNA damage, which normal but not transformed cells can repair. Proc Natl Acad Sci U S A (2010) 2.41
Immunomodulatory effects of deacetylase inhibitors: therapeutic targeting of FOXP3+ regulatory T cells. Nat Rev Drug Discov (2009) 2.00
MicroRNA-124 controls the proliferative, migratory, and inflammatory phenotype of pulmonary vascular fibroblasts. Circ Res (2013) 1.80
The clinical development of histone deacetylase inhibitors as targeted anticancer drugs. Expert Opin Investig Drugs (2010) 1.79
Emergence of fibroblasts with a proinflammatory epigenetically altered phenotype in severe hypoxic pulmonary hypertension. J Immunol (2011) 1.39
HDAC inhibitor increases histone H3 acetylation and reduces microglia inflammatory response following traumatic brain injury in rats. Brain Res (2008) 1.36
Histone deacetylase inhibitors: a chemical genetics approach to understanding cellular functions. Biochim Biophys Acta (2010) 1.35
HDAC inhibition attenuates inflammatory, hypertrophic, and hypertensive responses in spontaneously hypertensive rats. Hypertension (2010) 1.35
HDAC inhibition prevents white matter injury by modulating microglia/macrophage polarization through the GSK3β/PTEN/Akt axis. Proc Natl Acad Sci U S A (2015) 1.23
Reactive oxygen species-generating mitochondrial DNA mutation up-regulates hypoxia-inducible factor-1alpha gene transcription via phosphatidylinositol 3-kinase-Akt/protein kinase C/histone deacetylase pathway. J Biol Chem (2009) 1.19
Antifibrotic activity of an inhibitor of histone deacetylases in DOCA-salt hypertensive rats. Br J Pharmacol (2010) 1.16
Endoplasmic reticulum stress induced by surfactant protein C BRICHOS mutants promotes proinflammatory signaling by epithelial cells. Am J Respir Cell Mol Biol (2010) 0.98
Enhancement of vaccinia virus based oncolysis with histone deacetylase inhibitors. PLoS One (2010) 0.95
The antiepileptic drug valproic acid restores T cell homeostasis and ameliorates pathogenesis of experimental autoimmune encephalomyelitis. J Biol Chem (2012) 0.94
Targeting the adventitial microenvironment in pulmonary hypertension: A potential approach to therapy that considers epigenetic change. Pulm Circ (2012) 0.94
Myeloid-derived suppressor cells in multiple myeloma: pre-clinical research and translational opportunities. Front Oncol (2014) 0.94
Regulation of acetylation restores proteolytic function of diseased myocardium in mouse and human. Mol Cell Proteomics (2013) 0.91
Acetate supplementation modulates brain histone acetylation and decreases interleukin-1β expression in a rat model of neuroinflammation. J Neuroinflammation (2012) 0.90
Beyond receptors and signaling: epigenetic factors in the regulation of innate immunity. Immunol Cell Biol (2015) 0.88
STAT1 signaling is not regulated by a phosphorylation-acetylation switch. Mol Cell Biol (2011) 0.88
Acetate reduces microglia inflammatory signaling in vitro. J Neurochem (2012) 0.88
HDAC inhibitors stimulate viral transcription by multiple mechanisms. Virol J (2008) 0.87
Sirtinol treatment reduces inflammation in human dermal microvascular endothelial cells. PLoS One (2011) 0.87
Valproic acid: an anticonvulsant drug with potent antinociceptive and anti-inflammatory properties. Naunyn Schmiedebergs Arch Pharmacol (2013) 0.87
Histone acetyltransferase inhibitor C646 reverses epithelial to mesenchymal transition of human peritoneal mesothelial cells via blocking TGF-β1/Smad3 signaling pathway in vitro. Int J Clin Exp Pathol (2015) 0.85
Role of 5'TG3'-interacting factors (TGIFs) in Vorinostat (HDAC inhibitor)-mediated Corneal Fibrosis Inhibition. Mol Vis (2015) 0.84
Trichostatin A increases the TIMP-1/MMP ratio to protect against osteoarthritis in an animal model of the disease. Mol Med Rep (2016) 0.82
Histone Deacetylase Inhibitor Vorinostat (SAHA) Suppresses IL-1β-Induced Matrix Metallopeptidase-13 Expression by Inhibiting IL-6 in Osteoarthritis Chondrocyte. Am J Pathol (2016) 0.81
Epigenetic changes in p21 expression in renal cells after exposure to bromate. Toxicol Sci (2014) 0.81
Trichostatin A Modulates Angiotensin II-induced Vasoconstriction and Blood Pressure Via Inhibition of p66shc Activation. Korean J Physiol Pharmacol (2015) 0.81
Histone Deacetylase Inhibitor Trichostatin A Ameliorated Endotoxin-Induced Neuroinflammation and Cognitive Dysfunction. Mediators Inflamm (2015) 0.80
Acetate reduces PGE2 release and modulates phospholipase and cyclooxygenase levels in neuroglia stimulated with lipopolysaccharide. Lipids (2013) 0.79
Dynamic structure-based pharmacophore model development: a new and effective addition in the histone deacetylase 8 (HDAC8) inhibitor discovery. Int J Mol Sci (2011) 0.78
The role of Nox-mediated oxidation in the regulation of cytoskeletal dynamics. Curr Pharm Des (2015) 0.77
Regulation of intestinal serotonin transporter expression via epigenetic mechanisms: role of HDAC2. Am J Physiol Cell Physiol (2012) 0.76
Class I HDACs specifically regulate E-cadherin expression in human renal epithelial cells. J Cell Mol Med (2016) 0.76
A structure-activity relationship of non-peptide macrocyclic histone deacetylase inhibitors and their anti-proliferative and anti-inflammatory activities. Bioorg Med Chem (2015) 0.76
HDAC Inhibitors as Epigenetic Regulators of the Immune System: Impacts on Cancer Therapy and Inflammatory Diseases. Biomed Res Int (2016) 0.75
Fetal asphyctic preconditioning alters the transcriptional response to perinatal asphyxia. BMC Neurosci (2014) 0.75
Acetate supplementation modulates brain adenosine metabolizing enzymes and adenosine A₂A receptor levels in rats subjected to neuroinflammation. J Neuroinflammation (2014) 0.75
Antitumor mechanisms of amino Acid hydroxyurea derivatives in the metastatic colon cancer model. Int J Mol Sci (2013) 0.75
Histone deacetylase 3 supports endochondral bone formation by controlling cytokine signaling and matrix remodeling. Sci Signal (2016) 0.75
Effect of HDAC Inhibitors on Corneal Keratocyte Mechanical Phenotypes in 3-D Collagen Matrices. Mol Vis (2015) 0.75
Potent and orally efficacious bisthiazole-based histone deacetylase inhibitors. ACS Med Chem Lett (2014) 0.75
Combination strategies to enhance the potency of monocyte-derived dendritic cell-based cancer vaccines. Immunotherapy (2016) 0.75
Topical Ophthalmic Formulation of Trichostatin A and SurR9-C84A for Quick Recovery Post-alkali Burn of Corneal Haze. Front Pharmacol (2017) 0.75
Nuclear factor-kappaB in cancer development and progression. Nature (2006) 18.31
Epigenetics in human disease and prospects for epigenetic therapy. Nature (2004) 11.46
Duration of nuclear NF-kappaB action regulated by reversible acetylation. Science (2001) 6.79
The phosphorylation status of nuclear NF-kappa B determines its association with CBP/p300 or HDAC-1. Mol Cell (2002) 5.84
The p65 (RelA) subunit of NF-kappaB interacts with the histone deacetylase (HDAC) corepressors HDAC1 and HDAC2 to negatively regulate gene expression. Mol Cell Biol (2001) 4.55
Histone deacetylase (HDAC) inhibitor activation of p21WAF1 involves changes in promoter-associated proteins, including HDAC1. Proc Natl Acad Sci U S A (2004) 3.86
Clinical development of histone deacetylase inhibitors as anticancer agents. Annu Rev Pharmacol Toxicol (2005) 3.66
Glucocorticoid receptor recruitment of histone deacetylase 2 inhibits interleukin-1beta-induced histone H4 acetylation on lysines 8 and 12. Mol Cell Biol (2000) 3.13
Histone deacetylases induce angiogenesis by negative regulation of tumor suppressor genes. Nat Med (2001) 3.07
Histone deacetylase inhibitors. Adv Cancer Res (2004) 2.93
The histone deacetylase inhibitor ITF2357 reduces production of pro-inflammatory cytokines in vitro and systemic inflammation in vivo. Mol Med (2006) 2.11
Histone hyperacetylation is associated with amelioration of experimental colitis in mice. J Immunol (2006) 2.09
Transcriptional therapy with the histone deacetylase inhibitor trichostatin A ameliorates experimental autoimmune encephalomyelitis. J Neuroimmunol (2005) 1.89
Anti-rheumatic activities of histone deacetylase (HDAC) inhibitors in vivo in collagen-induced arthritis in rodents. Br J Pharmacol (2007) 1.77
Targeting histone deacetylase in cancer therapy. Med Res Rev (2006) 1.69
Histone deacetylase inhibitor suppression of autoantibody-mediated arthritis in mice via regulation of p16INK4a and p21(WAF1/Cip1) expression. Arthritis Rheum (2004) 1.67
A therapeutic strategy uses histone deacetylase inhibitors to modulate the expression of genes involved in the pathogenesis of rheumatoid arthritis. Mol Ther (2003) 1.59
Trichostatin A attenuates airway inflammation in mouse asthma model. Clin Exp Allergy (2005) 1.53
Butyrate inhibits NF-kappaB activation in lamina propria macrophages of patients with ulcerative colitis. Scand J Gastroenterol (2002) 1.52
Chromatin remodeling and transcriptional activation: the cast (in order of appearance). Oncogene (2001) 1.51
Histone deacetylase inhibitors: latest developments, trends and prospects. Curr Med Chem Anticancer Agents (2005) 1.19
Histone deacetylases augment cytokine induction of the iNOS gene. J Am Soc Nephrol (2002) 1.13
Butyrate suppresses Cox-2 activation in colon cancer cells through HDAC inhibition. Biochem Biophys Res Commun (2004) 1.13
Regulation of microglial inflammatory response by histone deacetylase inhibitors. J Neurochem (2003) 1.08
Paradoxical effects of trichostatin A: inhibition of NF-Y-associated histone acetyltransferase activity, phosphorylation of hGCN5 and downregulation of cyclin A and B1 mRNA. Cancer Lett (2001) 1.01
Trichostatin A, a histone deacetylase inhibitor, down-regulates interleukin-12 transcription in SV-40-transformed lung epithelial cells. Cell Immunol (2002) 1.01